| Literature DB >> 26432403 |
David Anz1, Moritz Rapp2, Stephan Eiber1, Viktor H Koelzer2, Raffael Thaler2, Sascha Haubner2, Max Knott2, Sarah Nagel2, Michaela Golic2, Gabriela M Wiedemann2, Franz Bauernfeind3, Cornelia Wurzenberger2, Veit Hornung4, Christoph Scholz5, Doris Mayr6, Simon Rothenfusser2, Stefan Endres7, Carole Bourquin8.
Abstract
The chemokine CCL22 is abundantly expressed in many types of cancer and is instrumental for intratumoral recruitment of regulatory T cells (Treg), an important subset of immunosuppressive and tumor-promoting lymphocytes. In this study, we offer evidence for a generalized strategy to blunt Treg activity that can limit immune escape and promote tumor rejection. Activation of innate immunity with Toll-like receptor (TLR) or RIG-I-like receptor (RLR) ligands prevented accumulation of Treg in tumors by blocking their immigration. Mechanistic investigations indicated that Treg blockade was a consequence of reduced intratumoral CCL22 levels caused by type I IFN. Notably, stable expression of CCL22 abrogated the antitumor effects of treatment with RLR or TLR ligands. Taken together, our findings argue that type I IFN blocks the Treg-attracting chemokine CCL22 and thus helps limit the recruitment of Treg to tumors, a finding with implications for cancer immunotherapy. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26432403 DOI: 10.1158/0008-5472.CAN-14-3499
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701